Analyst Hints & Ratings — November 03, 2026 — Midday Update — Last 24 Hours (Pacific Time)

Executive Summary

Analyst activity over the past 24 hours skewed broadly bullish, with price target raises outnumbering cuts and upgrades outpacing downgrades — though a cluster of notable downgrades (Marvell, Lumentum, monday.com, D.R. Horton, Alstom) added meaningful bearish counterweight. Stifel, Needham, Wells Fargo, and Citizens were among the most active firms, each covering a wide range of sectors. Key themes driving calls include AI-driven demand (Palantir, Tempus AI, Lattice Semiconductor), the Marvell-Lumentum acquisition reshaping semiconductor sentiment, Apple's post-earnings debate, and continued strength in digital health (Hinge Health) and specialty pharma (Vertex Pharmaceuticals).

Analyst Action Breakdown

Note: Some actions overlap (e.g. a downgrade with a PT cut is counted in both rows). Counts are based on distinct headline actions across all 199 items.

Net Sentiment: 🟢 Moderately Bullish
PT raises significantly outnumber cuts (~2:1), upgrades slightly trail downgrades in raw count but the magnitude of bullish PT moves (e.g. Vertex, Hinge Health, Palantir, L3Harris) outweighs the bearish ones. The downgrade cluster is concentrated in specific deal-driven situations (Marvell/Lumentum) rather than broad macro pessimism.

Top Analyst Calls

🔴 TD Cowen → Marvell Technology (MRVL) — Downgraded to Hold from Buy, PT cut to $175 from $350

• The Lumentum acquisition raised significant deal concerns, prompting a dramatic 50% price target reduction.

🔴 BofA → Marvell Technology (MRVL) — Downgraded to Neutral from Buy, PT cut to $225 from $350

• BofA joined TD Cowen in flagging concerns over the Lumentum deal terms.

🟢 Raymond James → Lumentum Holdings (LITE) — Upgraded to Strong Buy from Outperform, PT raised

• Raymond James sees the Marvell deal as value-accretive for Lumentum shareholders, taking the contrarian bullish view.

🔴 B.Riley → Lumentum Holdings (LITE) — Downgraded to Neutral from Buy, PT cut to $770

• B.Riley cited unfavorable Marvell deal terms as the reason for the downgrade.

🟢 Wells Fargo → Vertex Pharmaceuticals (VRTX) — PT raised to $650 from $550, maintains Overweight

• Manufacturing confidence underpins a significant $100 target increase on the CF franchise.

🟢 Piper Sandler → Palantir Technologies (PLTR) — PT raised to $235 from $231, maintains Overweight

• Strong revenue growth continues to drive incremental upside revisions across multiple firms.

🟢 RBC Capital → Palantir Technologies (PLTR) — PT raised to $130 from $90, maintains Sector Perform

• A notable $40 jump in target reflects strong quarterly results, even as the rating stays neutral.

🟢 BofA → L3Harris Technologies (LHX) — PT raised to $375 from $325, maintains Buy

• An earnings beat drove a significant $50 price target increase on the defense name.

🔴 Raymond James → D.R. Horton (DHI) — Downgraded to Underperform from Market Perform

• Valuation concerns following the homebuilder's results prompted a rare bearish downgrade.

🔴 TD Cowen → monday.com (MNDY) — Downgraded to Hold from Buy, PT cut to $105

• Top-of-funnel headwinds drove the downgrade of this enterprise software name.

🟢 BTIG → Tempus AI (TEM) — PT raised to $100 from $80, maintains Buy

• Data deal momentum is accelerating, with BTIG leading a wave of bullish Tempus AI revisions.

🟢 Needham → Ichor Holdings (ICHR) — PT cut to $55 from $88, maintains Buy

• A steep $33 target reduction on revenue outlook concerns, though the Buy rating is retained.

🟢 Wedbush → Apple (AAPL) — Reiterates Outperform, $400 PT

• Dan Ives stands firm at the Street's highest Apple target, citing iPhone strength amid a divided analyst community.

🔴 BNP Paribas Exane → Medical Properties Trust (MPT) — Downgraded to Neutral from Outperform, PT lowered

• Tenant concerns prompted the downgrade of this healthcare REIT.

🟢 Goldman Sachs → Ibotta (IBTA) — Upgraded to Neutral from Sell, PT raised to $58 from $35

• A meaningful sentiment shift from Goldman, upgrading from Sell on platform progress.

Firm Activity Summary

Stifel — 12 calls (9 bullish, 3 bearish)

• CMPS (Buy reiterated), FANG (Buy reiterated), TSEM (PT cut), VRTX (PT raised), INSP (Buy reiterated), PM (PT raised), HNGE (PT raised), BMRN (PT cut), SPTX (Buy reiterated), LSCC (PT raised), CHKP (PT raised), TRXB (initiated Buy)

Needham — 11 calls (9 bullish, 2 bearish)

• EVER (PT raised), ICHR (PT cut), SIBN (PT cut), ON (Buy reiterated), LASR (initiated Buy), MRVL (PT cut), UPWK (PT raised), IBTA (PT raised), ROKU (Buy reiterated), EBAY (Buy reiterated), HNGE (PT raised)

Wells Fargo — 10 calls (7 bullish, 3 bearish)

• ON (PT cut), HNGE (PT raised), AEIS (PT cut), INSP (PT raised), VRTX (PT raised), OLN (PT raised), IBTA (PT raised), AAPL (PT cut), CLX (PT raised), MAR (PT raised), CIFR (PT cut), EL (PT raised)

StoneX — 9 calls (5 bullish, 4 neutral/bearish)

• GRAB (PT cut), LSCC (Buy reiterated), APTV (Buy reiterated), ITGR (Hold reiterated), RXO (Hold reiterated), BATRA (Buy reiterated), PLTR (Hold reiterated), MRVL (Buy reiterated), TSEM (Buy reiterated)

Citizens — 9 calls (8 bullish, 1 neutral)

• SUI (Outperform reiterated), SBAC (Outperform reiterated), SIBN (Outperform reiterated), MFA (Outperform reiterated), FOXA (Outperform reiterated), CRSP (Outperform reiterated), LIFE (PT raised), BLZE (Outperform reiterated)

DA Davidson — 7 calls (5 bullish, 2 neutral/bearish)

• SHOP (PT cut), BCC (Buy reiterated), SXI (Buy reiterated), SGC (Buy reiterated), TLS (Neutral reiterated), NSSC (PT cut), AAPL (PT raised, Neutral)

Cantor Fitzgerald — 6 calls (4 bullish, 2 neutral)

• EPRT (PT cut), BMRN (Overweight reiterated), AEIS (Overweight reiterated), VRTX (PT raised), NBIX (Overweight reiterated), ON (Neutral reiterated)

BTIG — 7 calls (4 bullish, 3 neutral)

• CMPS (Buy reiterated), ETR (PT raised), UPWK (Neutral reiterated), PLTR (Hold reiterated), CHKP (Neutral reiterated), HWM (PT cut), NTSK (PT raised), TEM (PT raised), DRUG (PT cut)

B.Riley — 7 calls (4 bullish, 3 bearish)

• TATT (PT raised), MSTR (PT cut), EVER (PT raised), AXSM (Buy reiterated), FN (PT cut), ON (PT cut), LITE (downgraded, PT cut)

TD Cowen — 7 calls (4 bullish, 3 bearish)

• RCEL (PT raised), CLX (PT raised, Hold), TEAM (PT raised), VRTX (PT raised), CHD (PT raised, Hold), MNDY (downgraded), MRVL (downgraded)

Wedbush — 7 calls (5 bullish, 2 neutral)

• AAPL (Outperform reiterated), TSEM (PT cut), OKLO (initiated Outperform), GFUZ (initiated Neutral), NNE (initiated Outperform), XE (initiated Outperform), IMSR (initiated Neutral), SMR (initiated Underperform)

UBS — 7 calls (4 bullish, 3 neutral/bearish)

• MRVL (Buy reiterated), SONVY (downgraded), PTGX (Buy reiterated), IOVA (PT raised), AXSM (PT cut), IDXX (PT raised), AAPL (PT raised, Neutral), PLTR (Buy reiterated), ADDYY (downgraded to Sell)

JPMorgan — 6 calls (2 bullish, 4 bearish)

• TRXB (initiated Overweight), CIFR (PT cut), SBAC (PT cut), VRTX (PT raised), AAPL (PT cut), VRRM (downgraded to Underweight), ALO (downgraded)

Goldman Sachs — 4 calls (2 bullish, 1 neutral, 1 bearish)

• PLTR (Buy reiterated), IBTA (upgraded to Neutral), MRNA (Neutral reiterated), CLX (Sell reiterated)

BMO Capital — 3 calls (2 bullish, 1 bearish)

• MRSH (upgraded to Outperform), AON (upgraded to Outperform), AJG (downgraded to Market Perform)

Raymond James — 4 calls (2 bullish, 1 neutral, 1 bearish)

• CBNA (PT raised), ABNB (Outperform reiterated), FDXF (PT cut), DHI (downgraded to Underperform), LITE (upgraded to Strong Buy)

Baird — 5 calls (3 bullish, 2 neutral)

• PLTR (Outperform reiterated), LULU (Neutral reiterated), NBIX (Outperform reiterated), JAZZ (Outperform reiterated), LSCC (PT raised), AAPL (PT raised)

Canaccord — 4 calls (4 bullish)

• WAY (PT raised), HNGE (PT raised), SIBN (Buy reiterated), EVER (PT raised)

H.C. Wainwright — 4 calls (4 bullish)

• TEM (PT raised), URGN (Buy reiterated), BWAY (Buy reiterated), SNDX (PT cut), CIFR (Buy reaffirmed)

Scotiabank — 3 calls (1 bullish, 2 bearish)

• UPWK (PT raised, Sector Perform), CHKP (PT cut), GIL (PT cut)

Mizuho — 3 calls (2 bullish, 1 neutral)

• PLTR (Outperform reiterated), SNDX (Outperform reiterated), LITE (PT cut)

Deutsche Bank — 2 calls (1 bullish, 1 bearish)

• AMKBY (PT raised), ALO (PT cut)

Jefferies — 3 calls (1 bullish, 2 bearish)

• AEP (PT raised), TEM (upgraded to Hold), FUPBY (downgraded to Hold)

Truist — 4 calls (2 bullish, 2 bearish)

• INSP (PT cut), XZO (PT cut), WAY (Buy reiterated), PLTR (PT raised)

Sector Trends

Technology & Semiconductors — Divergent Signals, Deal-Driven Chaos
The Marvell-Lumentum acquisition dominated semiconductor coverage, creating a sharp split: Marvell received two downgrades (BofA, TD Cowen) with steep price target cuts, while Lumentum saw a Raymond James upgrade to Strong Buy alongside downgrades from B.Riley and Needham. Elsewhere in chips, Lattice Semiconductor attracted broad bullishness with PT raises from Baird, Stifel, and Rosenblatt on AI momentum, while Tower Semiconductor saw cuts from both Stifel and Wedbush on valuation and market headwinds. ON Semiconductor faced a wall of PT cuts (Wells Fargo, B.Riley, Needham) despite mixed Buy reiterations, reflecting ongoing automotive/industrial demand uncertainty.

AI & Data Infrastructure — Consensus Bullish
Palantir Technologies was the single most-covered name of the session, attracting PT raises from Piper Sandler, Truist, Morgan Stanley, RBC Capital, and UBS, alongside Buy reiterations from Goldman Sachs, Baird, Rosenblatt, and Mizuho — all following a strong quarterly report. Only StoneX held firm at Hold. Tempus AI also saw aggressive PT raises from BTIG ($100 from $80) and H.C. Wainwright ($85 from $68), with Jefferies upgrading from Underperform to Hold. The AI theme is clearly the dominant bullish driver across multiple sectors.

Healthcare & Pharma — Mostly Constructive, Select Cuts
Vertex Pharmaceuticals attracted one of the session's most concentrated bullish clusters, with PT raises from Wells Fargo ($650), Cantor Fitzgerald ($619), Stifel ($563), TD Cowen ($575), and JPMorgan ($570) — all citing CF franchise durability and pipeline confidence. Hinge Health (digital health) also saw broad PT raises from Needham, Canaccord, Stifel, and Wells Fargo on strong billings and client growth. On the bearish side, BioMarin received a PT cut from Stifel and Oppenheimer on growth concerns and guidance cuts, while Inspire Medical Systems saw a mixed picture with Wells Fargo raising and Truist cutting targets.

Market Implications

The sheer volume of Palantir upgrades and PT raises — from eight distinct firms in a single session — signals that the AI monetization story is no longer speculative; analysts are now competing to justify higher valuations based on actual revenue delivery. For investors, this creates a crowded consensus trade where the risk is not the thesis but the entry price. The divergence between StoneX (Hold) and the rest of the Street is worth watching as a contrarian signal.

The Marvell-Lumentum deal is the session's clearest example of analyst bifurcation. Two major banks (BofA, TD Cowen) cut Marvell aggressively while StoneX and UBS held their Buy ratings. Raymond James flipped bullish on Lumentum while B.Riley and Needham cut. This kind of sharp disagreement typically signals genuine uncertainty about deal economics — investors should expect elevated volatility in both names until the deal closes and synergies become clearer.

Apple remains the Street's most debated mega-cap. In a single session, it attracted an Outperform from Wedbush ($400 target), a Sell from Aletheia Capital ($250), an Underweight from KeyBanc ($250), and PT adjustments from Morgan Stanley, UBS, Baird, Evercore ISI, Bernstein, JPMorgan, and DA Davidson — spanning a target range from $250 to $400. This extraordinary spread reflects genuine disagreement on Services growth trajectory and iPhone upgrade cycle durability. With no consensus, Apple is effectively a stock where firm selection matters as much as the call itself.

👉 Vlad's Hints & Key Takeaways

• 🔴 Marvell Technology (MRVL) — Two major downgrades (BofA, TD Cowen) with targets slashed ~50% on Lumentum deal concerns; the acquisition is reshaping the entire semiconductor analyst landscape.
• 🟢 Palantir Technologies (PLTR) — The session's most-covered stock with PT raises from 5+ firms post-earnings; AI revenue delivery is converting skeptics into believers.
• 🟢 Vertex Pharmaceuticals (VRTX) — Five firms raised price targets in a single session, with Wells Fargo's $650 target leading the pack; CF franchise durability is the consensus thesis.
• 🟢 Lumentum Holdings (LITE) — Raymond James upgraded to Strong Buy on Marvell deal value, directly contradicting B.Riley's downgrade; deal outcome remains the key variable.
• 🟢 Hinge Health (HNGE) — PT raises from Needham, Canaccord, Stifel, and Wells Fargo in one session signal strong conviction in digital musculoskeletal health growth.
• 🟢 L3Harris Technologies (LHX) — BofA raised PT to $375 from $325 on an earnings beat; defense spending tailwinds remain intact.
• 🔴 D.R. Horton (DHI) — Raymond James downgraded to Underperform, a rare bearish call on the largest U.S. homebuilder; valuation concerns post-results.
• 🔴 monday.com (MNDY) — TD Cowen downgraded to Hold from Buy on top-of-funnel headwinds; enterprise software demand softening is a broader concern.
• 🟢 Tempus AI (TEM) — BTIG raised PT to $100 from $80; Jefferies upgraded from Underperform to Hold; sentiment is clearly improving on data deal momentum.
• 🔴 Tower Semiconductor (TSEM) — Both Stifel and Wedbush cut price targets (to $235 and $190 respectively) on valuation and market headwinds, despite StoneX maintaining Buy at $335.
• 🟢 Lattice Semiconductor (LSCC) — PT raises from Baird ($195), Rosenblatt ($200), and Stifel ($175) on AI momentum; a quieter but consistent bullish consensus.
• 🔴 Ichor Holdings (ICHR) — Needham cut PT to $55 from $88 (a $33 drop) while Stifel cut to $93 from $115; component constraints are hitting this semiconductor equipment supplier hard.
• 🟢 Goldman Sachs upgrades Ibotta (IBTA) — A Sell-to-Neutral upgrade from Goldman is a meaningful sentiment shift; platform progress is reducing the bear case.
• 🔴 Alstom (ALSMY) — Both JPMorgan (downgraded to Neutral) and Deutsche Bank cut targets on a profit warning; European industrial weakness is real.
• 🟢 Wedbush initiates nuclear energy cluster — Outperform ratings on Oklo, Nano Nuclear, and X-Energy signal growing institutional interest in next-gen nuclear; NuScale Power received the lone Underperform.
• 🔴 Bright Minds Biosciences (DRUG) — BTIG slashed PT to $37 from $147 on a clinical hold; a devastating 75% target cut for this small-cap biotech.
• 🟢 BMO upgrades Aon (AON) and Marsh (MRSH) — Simultaneous upgrades of two insurance brokers while downgrading Arthur J. Gallagher signals a rotation within the sector toward larger-cap names.
• 🟡 Apple (AAPL) — Price targets range from $250 (bears) to $400 (Wedbush); with 10+ firms weighing in, this is the Street's most divided mega-cap call of the session.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

👉 This is not financial advice. Market conditions change rapidly. Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/